K. Gong
JPMorgan Chase & Co, Research Division
Okay. Thanks, everyone, for coming today. My name is Allen Gong, here on the JPMorgan Medtech team. I’m really excited to have the management team of iRhythm here today this morning. We’re going to start off with some prepared remarks from CEO, Quentin Blackford, and then we’re going to tag in Dan Wilson, CFO, for some Q&A after that. So Quentin, if you could start us off.
Quentin Blackford
President, CEO & Director
Terrific. Can you guys hear me okay? Thanks for having us, Allen. We appreciate the opportunity to be here. We’re excited to be here, coming off of an incredible 2025 for iRhythm, and we’re looking forward to an even more exciting 2026. As we look ahead, just a quick reminder, I will be using forward-looking statements during the course of this morning’s presentation. I’d refer you to our company website, company filings for any further information that you might be looking for there.
When a signal changes everything, when we talk about signals in arrhythmias, we’re not talking about just any one particular thing, signal show up in a variety of different ways. And it’s the complexity of that, that creates the challenge for players in this space, for us, it also becomes the opportunity. We think about how these signals show up in practice on a daily basis, sometimes it’s a story like Carissa, who finds herself in the ER, dealing with severe health issues, only to have an EKG performed and told her that everything is perfectly fine. She is sent home, no issues. She finds
